COVID-19: Solnatide approved for compassionate use
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2152 entries already.
Entries by Thomas Gabrielczyk
GE renamed Cytiva upon take-over by Danaher
Following the completion of Danaher’s €19.5bn take-over of GE Healthcare Life Sciences, GE’s CDMO arm is renamed Cytiva.
Making opoids more effective pain killers
Low intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.
Apeptico gets EU grant for COVID-19 drug
Austrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients
CHMP greenlights Novartis’ Zolgensma
The European Medicines Agency EMA has backed eight medicines for approval at its virtual March 2020 meeting.
New resource models human metabolism
Scandinavian researchers have created a unified, open-source model providing a genome-wide portrait of human disease metabolism.
Novacyt inks contract on Covid-19 diagnostics
Paris-based Novacyt SA has signed a global distribution agreement with Bruker Ltd for its COVID-19 diagnostic test.
AC Immune SA gets Lilly milestone for Alzheimers’ candidate
AC Immune SA has received a milestone payment of CHF10m from Eli Lilly and Company.
Experts discuss link between sepsis and Covid-19
Scientists have discussed a link between Covid-19 and sepsis at a virtual symposium at Charité Berlin that might help reduce the burden of end-stage disease.
Evonik Industries AG establishes production of recombinant collagen
Evonik Industries has established a new animal-free and fermentation-based industrial-scale recombinant collagen production platform.